Multidisciplinary Care Ensures ‘Comfort’ in Decisions Surrounding Lumpectomy for Breast Cancer Subtype, Says Expert

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota, details the multidisciplinary work that goes into delivering breast-conserving therapy for patients with multiple ipsilateral breast cancer.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Judy C. Boughey, MD, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about the collaborative, multidisciplinary considerations that go into breast-conserving therapy for patients with multiple ipsilateral breast cancer.

According to Boughey, patients receiving breast conservation therapy will get the full value of a multidisciplinary team including breast surgeons, radiation oncologists, and medical oncologists.

Transcript:

All of breast cancer care these days is very much multidisciplinary. For these patients with multiple ipsilateral breast cancer, it does bring the value of a multidisciplinary team’s input into that patient's care. If the patient chooses to proceed with breast-conserving therapy, that's going to involve not only surgical resection, but also the incorporation of adjuvant whole breast radiation.

We want to make sure that the patient and the radiation oncologists are comfortable proceeding with the radiation aspects, and then also to incorporate the medical oncologist in terms of the systemic therapy recommendations.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
Related Content